Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAE1 | Q9UBE0 | 11/20 | 1.00 |
| ▸ | UBA2 | Q9UBT2 | 11/20 | 1.00 |
| ▸ | CASP1 | P29466 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | CASP7 | P55210 | 6/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CASP6 | P55212 | 3/20 | 1.00 |
| ▸ | THRB | P10828 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | NSD2 | O96028 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27085541 | 0.89 | SAE1 (0.80) | SAE1UBA2CASP1HSD17B10MEN1 | |
| SCHEMBL15256907 | 0.87 | SAE1 (1.00) | SAE1UBA2CASP1HSD17B10MEN1 | |
| SCHEMBL4787152 | 0.87 | SAE1 (0.85) | SAE1UBA2CASP1HSD17B10MEN1 | |
| SCHEMBL4787869 | 0.86 | SAE1 (1.00) | SAE1UBA2CASP1HSD17B10MEN1 | |
| SCHEMBL6980630 | 0.85 | KMT2A (1.00) | SAE1UBA2CASP1HSD17B10MEN1 | |
| SCHEMBL27085538 | 0.84 | SAE1 (0.74) | SAE1UBA2CASP1HSD17B10MEN1 | |
| SCHEMBL30754257 | 0.84 | SAE1 (0.74) | SAE1UBA2CASP1HSD17B10MEN1 | |
| SCHEMBL15256873 | 0.84 | SAE1 (0.87) | SAE1UBA2CASP1HSD17B10MEN1 | |
| SCHEMBL4787545 | 0.83 | SAE1 (1.00) | SAE1UBA2CASP1HSD17B10MEN1 | |
| SCHEMBL15256874 | 0.83 | SAE1 (1.00) | SAE1UBA2CASP1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045483-B2 | Inhibition of small ubiquitin-like modifier enzymes with substituted pyrrolo[2,3-b]quinoxalines | CITY OF HOPE (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045483-B2 | Inhibition of small ubiquitin-like modifier enzymes with substituted pyrrolo[2,3-b]quinoxalines | CITY OF HOPE (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130245032-A1 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS OF THEIR USE | Sanford-Burnham Medical Research Institute at Lake Nona (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245032-A1 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS OF THEIR USE | Sanford-Burnham Medical Research Institute at Lake Nona (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2012064897-A2 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS FOR THEIR USE | CHEN YUAN (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245032-A1 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS OF THEIR USE | SUMO1, SUMO2, SAE1 | SAE1 3/4885UBA2 4/4885CASP1 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.